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The optimal dose of a medication is that which provides the
most acceptable balance of benefit and risk for an indivi-
dual patient. Achieving this can be complicated, and an
optimal dose for an individual will be affected by numerous
patient, disease, and health-care resource factors. For chil-
dren, the complexity is greater still, as many older medi-
cines were developed when regulations did not require
specific pediatric assessments. Even for newer drugs,
where regulations in the U.S. and EU now mean that there
are early-phase studies in children upon which to base the
doses, there are still gaps in the evidence base such as re-
purposing of the drugs beyond their licensed indication(s).
There are also important patient differences to consider,
such as growth, alterations in body composition, ontogeny
of drug metabolizing enzymes, and obesity, which affect the
optimal dose of a medicine in children. These problems can
be even more pronounced in neonates and preterm infants,
and specifics of dosing relating to neonates have recently
been reviewed [1].
Worldwide, children still experience considerable morbidity
and mortality, with over seven million deaths in childhood per
year [2]. While optimizing dosage is important for the treat-
ments of the major causes of childhood mortality (lower
respiratory tract infections and diarrheal illnesses), as well as
conditions such as TB, HIV, and malaria, they form part of
broader package. As the WHO initiative around HIV therapy
shows [3], focus is also needed many other aspects of health
care, such as simplifying treatment regimens to allow wide-
spread utilization.
In developed nations, childhood mortality is considerably
lower. Of the medicines used, analgesia, antibiotics, and anti-
asthmatic medications dominate inpatient prescribing for chil-
dren [4]. In addition, there are between 6 and 8000 rare
diseases [5].
The combination of these multiple rare diseases and his-
toric exclusion from the drug development process explains
why many of the medications prescribed for children are given
‘off-label’ – outside their licensed indication [6]. Pediatricians
are encouraged to use evidence, not label indication, as the
gold standard when selecting treatments [7]. On the other
hand, higher rates of adverse drug reactions (ADRs) have
been noted with off-label and unlicensed medicines in
children [8], which would suggest that there is a good case
for looking at dose optimization in the older medicines.
Intravenous salbutamol for acute severe asthma is a good
example of how the dose of older medicines may be well
established, but may not be optimal. Both the 2014 British
Thoracic Society guidelines [9] and the British National
Formulary for Children [10] recommend an initial loading
dose of 15 µg/kg. At the Royal Melbourne children’s hospital
in Australia, the loading dose is 0.3–0.6 mg/kg over an hour
[11], while in Starship Children’s hospital New Zealand, the
dose is 10 mg/kg over 2 min [12]. These doses appear to be
derived from a single Australian randomized controlled trial
conducted in 1997 [13]. This trial involved 29 children, only 14
of whom received the active drug. This regimen means that
children aged 2 and above who weigh 20 kg or over will
receive the same bolus dose as an adult [14].
Pharmacokinetic simulations predict that this dosing regimen
puts children at significant risk of experiencing systemic sal-
butamol concentrations in the toxic range, and thus increases
the risk of adverse effects [14].
Newer drugs used in children are not exempt from issues
around dosing as well. Since the U.S. Best Pharmaceuticals for
Children Act [15], and European Union Pediatric Drug
Regulation [16], pharmaceutical companies hoping to bring
new medicines to market have been incentivized to develop
the pediatric uses of medicines. This has led to an increase in
the proportion of clinical trials involving children [17].
However, there are still issues around dosing; incorrect dose
selection contributes to failure of 23% of drug development
trials in children [18], while re-purposing of medicines to
additional indications in children remains commonplace.
Rituximab, a monoclonal antibody which causes lysis of
B-lymphocytes, has received a license for use in adults for
the treatment of non-Hodgkin’s lymphoma, chronic lympho-
cytic leukemia, rheumatoid arthritis, and granulomatosis with
polyangiitis and microscopic polyangiitis. The originator pro-
duct (Mabthera) is not licensed to treat children in the U.S. or
U.K. [19,20], yet is being used for an increasing number of
indications. In a large secondary and tertiary pediatric center
in the U.K., we have identified that rituximab is being used for
17 different indications [21]. Children with different conditions
receive varied doses and dosing intervals, such that
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annualized doses administered range from 750 to 2250 mg/m2
[21]. The origin of these dose variations is unclear.
Despite these difficulties, there is progress being made.
Aminoglycoside antibiotics, such as gentamicin and tobramy-
cin, have well-established efficacy and toxicity. Improved under-
standing of the physiological changes in neonates has helped
improve the dosing of gentamicin in the treatment of neonatal
sepsis. Due to the low glomerular filtration rate (GFR) in neo-
nates, clearance of gentamicin is reduced. To account for this,
extended-interval dosing has been developed (between 24 and
48 h) [10]. While GFR is low, neonates also have a high percen-
tage of body water compared to all other age groups. They
therefore demonstrate a relatively larger volume of distribution
for aminoglycosides. Neonates therefore require relatively larger
doses of gentamicin to achieve the high peak concentrations
required for their concentration-dependent antibacterial effect,
whilst extended interval dosing allows for adequate clearance,
reducing the risk of renal toxicity [22].
In children with cystic fibrosis (CF), higher doses of intrave-
nous aminoglycosides are required to treat respiratory exacer-
bations. There are a number of reasons for this dose
adjustment. There are resistant organisms (in particular
Pseudomonas aeruginosa) that require higher peak concentra-
tions for adequate antimicrobial effect. These higher circulat-
ing concentrations are also required to ensure adequate
penetration of the antibiotic to the site of infection in the
lung [23]. Furthermore, patients with CF have a larger volume
of distribution and greater clearance of aminoglycosides [23]
than other children of a similar age. Whilst higher doses are
required for adequate antimicrobial effect, extended-interval
dosing (usually every 24 h) has been demonstrated to reduce
nephrotoxicity [24].
However, as some problems are solved, new ones can
appear. In many countries, the proportion of obese children
is increasing. Pharmacokinetic data for obese patients do not
exist for many drugs [25], especially in children. Current pedia-
tric dosing often uses age bands, which do not take account of
weight at all, or vary the dose according to actual body weight
(e.g. mg/kg). This takes account of the weight, but has limita-
tions. One of these is with drugs that have a small volume of
distribution, and are primarily retained in the intravascular
compartment. Growth hormone is a drug with these charac-
teristics. When treatment outcomes (height, and change in
insulin-like growth factor 1 (IGF-1), a marker of metabolic
syndrome, and insulin resistance) following mg/kg actual dos-
ing of recombinant human growth hormone have been com-
pared with the patient’s body mass index at start of treatment
[26], patterns emerge. The thinnest children had the least
growth, while the obese children (already at risk of insulin
resistance) did not grow more than overweight children, but
had markedly greater increases in IGF-1 [26]. Evidence-based
dosing in children must include an understanding of how
obesity affects both the pharmacokinetics and pharmacody-
namics of a medicine [27]. Future studies will need to identify
the most important measure to use for dosing to improve
outcomes for both thin and obese children.
If actual body weight is not providing the best dose, then
other options include age bands, ideal body weight (IBW), lean
bodyweight (LBW), body surface area (BSA), or allometric scaling.
Age bands are easy to use in clinical practice, but can be very
inaccurate, and requires the drug in question to have a wide
therapeutic index to be safe [28]. IBW and LBWmay have advan-
tages for drugs that are predominantly intravascular, but there
are few dose optimization studies comparing actual weight with
either ideal or lean body weight in children. BSA may have
advantages over actual body weight, but can over-predict clear-
ance in neonates, while the more complex calculation makes it
harder to use in routine clinical practice [29]. Allometric scaling is
superior to actual body weight and BSA for scaling some phar-
macokinetic (PK) parameters such as plasma clearance, volume
of distribution and elimination half-life, but is a very complex
calculation that is not routinely used in clinical practice [28,30].
There is no single solution to achieve optimal dosing for
medicines in children, but awareness that there may be a pro-
blem is a good start. With many of the diseases treated being
rare, there is limited opportunity for large-scale randomized
controlled trials to establish optimal dosing. Instead, smaller
studies could be undertaken in children, to examine the link
between pharmacokinetic parameters and clinically important
pharmacodynamic outcomes (both efficacy and harm). However,
pharmacokinetic studies can be difficult to undertake in children
due to the burden of frequent blood tests. They can also be
expensive, as the studies come with significant regulatory bur-
dens, especially if the drug is used in children off-label.
Extrapolation of information and conclusions from adult data
to children, if done robustly, can reduce the amount of additional
information required frompediatric studies. Extrapolation can be
done if the disease is similar in adults and children, the expected
mechanism of action of the drug is the same in children, and if
the pharmacokinetic–pharmacodynamic relationship is the
same. Modeling and simulation approaches may then be used
to navigate the pediatric study decision tree proposed by the
European Medicines Agency (EMA) [31] in order to optimize the
design of pediatric studies and minimize the additional data
required. Population PK models, created using existing adult
data, can be used to identify the factors influencing variability,
which will inform the data required in children. For instance, a
population PK model of ceftaroline in adults identified creatinine
clearance as the primary determinant of exposure [32]. Pediatric
PK studies were designed to provide adequate data across age
groups, and weremainly focused on PK and safety data. The data
from these was used to update the population PKmodel, and the
new model used to run simulations to predict important phar-
macodynamic outcomes (percentage of time above minimum
inhibitory concentration) [33]. This model directly led to dosing
recommendations in children which were different from those
used in the trials, and have been accepted by both EMA and US
FDA. Similar work has been undertaken in neonates using cefa-
zolin [34]. Physiologically based PKmodels can also been used to
predict the impact of maturation on factors affecting PK. The
advantages of this approach are clear in terms of informing the
most appropriate study designs in children, and in particular to
minimize the numbers of children required, and the burden of
the studies in terms of time and frequency of sampling.
For existing medicines, perhaps the simplest first step
toward optimizing the dose would be improving the
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identification, and quantification, of harm from medicines
given to children. There is evidence that the under-reporting
noted for ADRs in national spontaneous reporting schemes
is as true for children and neonates [35,36] as for adults. As
we have seen, knowledge of the potential for nephrotoxicity
with aminoglycosides, and an understanding of their phar-
macokinetics, has resulted in steps to optimize the dosage.
Secondly, it is important to collect data on efficacy of med-
icines in children. Unlike ADRs where post-marketing surveil-
lance is generally conducted through national reporting
schemes, schemes collecting efficacy data are not widely
utilized. The best examples are in disease-specific registries,
such as the UK CF Registry [37] which collects efficacy data
related to CF-specific therapies. High-quality pharmacody-
namic data from large pediatric cohorts would allow atten-
tion to be focussed on the drugs causing greatest harm to
children, leading to optimization of dosage, in order to
maximize efficacy and minimize harm.
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